EA201490773A1 - EXTRACTIONS OF EXPOSURE - Google Patents
EXTRACTIONS OF EXPOSUREInfo
- Publication number
- EA201490773A1 EA201490773A1 EA201490773A EA201490773A EA201490773A1 EA 201490773 A1 EA201490773 A1 EA 201490773A1 EA 201490773 A EA201490773 A EA 201490773A EA 201490773 A EA201490773 A EA 201490773A EA 201490773 A1 EA201490773 A1 EA 201490773A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- acid salt
- salt
- acid
- extractions
- exposure
- Prior art date
Links
- 238000000605 extraction Methods 0.000 title 1
- 150000004923 Erlotinib derivatives Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical class OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 abstract 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical class OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001278 adipic acid derivatives Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 150000002688 maleic acid derivatives Chemical class 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Изобретение относится к солям эрлотиниба, выбранным из группы, включающей соль малеиновой кислоты, соль салициловой кислоты, соль L-миндальной кислоты, соль адипиновой кислоты, соль 1,5-нафталин-дисульфокислоты, соль L-пироглутаминовой кислоты, соль 1-гидрокси-2-нафтойной кислоты и соль (D,L)-миндальной кислоты, а так же их аморфные и кристаллические формы, гидраты и сольваты. Соли эрлотиниба согласно настоящему изобретению являются полезными в терапии, в частности, для лечения или профилактики немелкоклеточной карциномы легкого и рака поджелудочной железы.The invention relates to erlotinib salts selected from the group consisting of maleic acid salt, salicylic acid salt, L-mandelic acid salt, adipic acid salt, 1,5-naphthalene disulfonic acid salt, L-pyroglutamic acid salt, 1-hydroxy-2 salt -naphthoic acid and a salt of (D, L) -amidic acid, as well as their amorphous and crystalline forms, hydrates and solvates. Erlotinib salts of the present invention are useful in therapy, in particular for the treatment or prophylaxis of non-small cell lung carcinoma and pancreatic cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1100562A HU230483B1 (en) | 2011-10-10 | 2011-10-10 | Erlotinib salts |
| PCT/HU2012/000102 WO2013054147A2 (en) | 2011-10-10 | 2012-10-10 | Erlotinib salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201490773A1 true EA201490773A1 (en) | 2014-10-30 |
Family
ID=89990469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201490773A EA201490773A1 (en) | 2011-10-10 | 2012-10-10 | EXTRACTIONS OF EXPOSURE |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2776406A2 (en) |
| CN (1) | CN103958483A (en) |
| BR (1) | BR112014008733A2 (en) |
| EA (1) | EA201490773A1 (en) |
| HU (1) | HU230483B1 (en) |
| WO (1) | WO2013054147A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014118737A1 (en) * | 2013-01-31 | 2014-08-07 | Ranbaxy Laboratories Limited | Erlotinib salts |
| CN104250230A (en) * | 2014-09-05 | 2014-12-31 | 亿腾药业（泰州）有限公司 | Erlotinib citrate, crystal form and preparation method of two |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69536015D1 (en) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Quinazolinone derivatives |
| WO1999055683A1 (en) | 1998-04-29 | 1999-11-04 | Pfizer Products Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| US7960545B2 (en) * | 2005-11-23 | 2011-06-14 | Natco Pharma Limited | Process for the prepartion of erlotinib |
| EP2139868B1 (en) | 2007-04-04 | 2015-07-29 | Cipla Limited | Process for preparation of erlotinib and its pharmaceutically acceptable salts |
| CN102438995B (en) * | 2009-03-26 | 2014-12-17 | 兰贝克赛实验室有限公司 | Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof |
| WO2011068403A2 (en) * | 2009-12-02 | 2011-06-09 | Ultimorphix Technologies B.V. | Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts |
-
2011
- 2011-10-10 HU HU1100562A patent/HU230483B1/en not_active IP Right Cessation
-
2012
- 2012-10-10 EP EP12826647.5A patent/EP2776406A2/en not_active Withdrawn
- 2012-10-10 WO PCT/HU2012/000102 patent/WO2013054147A2/en active Application Filing
- 2012-10-10 BR BR112014008733A patent/BR112014008733A2/en not_active IP Right Cessation
- 2012-10-10 EA EA201490773A patent/EA201490773A1/en unknown
- 2012-10-10 CN CN201280058335.8A patent/CN103958483A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013054147A2 (en) | 2013-04-18 |
| HUP1100562A2 (en) | 2013-05-28 |
| CN103958483A (en) | 2014-07-30 |
| EP2776406A2 (en) | 2014-09-17 |
| BR112014008733A2 (en) | 2017-04-25 |
| WO2013054147A3 (en) | 2013-06-13 |
| HU230483B1 (en) | 2016-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119422T1 (en) | BETOULINE PRODUCERS | |
| EA201391615A1 (en) | DATED POTENTIATORS CFTR | |
| EA201590879A1 (en) | ARYL-CONDENSED AND HETEROARYL-CONDENSED LACTAMS | |
| EA201101583A1 (en) | PI3 KINASE OR MTOR INHIBITORS | |
| UA111770C2 (en) | BROMDOMEN INHIBITORS | |
| EA201270339A1 (en) | SUBSTITUTED DERIVATIVES OF XANTHINE | |
| EA201490673A1 (en) | DERIVATIVES OF PYRROLOPYRIMIDINE AND PURIN | |
| EA201590230A1 (en) | COMPOUNDS OF Pyrazolopyrimidine as kinase inhibitors | |
| EA201490357A1 (en) | INTRODUCTION | |
| EA201201161A1 (en) | PYRROPYRIMIDINES AS CDK4 / 6 INHIBITORS | |
| EA201590371A1 (en) | 1,4-DESIGNED PYRIDAZIN ANALOGUES AND METHODS OF TREATMENT RELATED TO SMN DEFICIENCY CONDITIONS | |
| UA111841C2 (en) | BENZOTHIAZOL COMPOUNDS AND THEIR PHARMACEUTICAL APPLICATION | |
| EA201270752A1 (en) | KINASE INHIBITORS AND METHOD FOR TREATING MALIGNANT TUMOR WITH THEIR HELP | |
| EA201490971A1 (en) | DERIVATIVES OF URACIL AS AXL AND C-MET KINASE INHIBITORS | |
| EA201000484A1 (en) | THYENOPYRIMIDINE AND PYRAZOLOPIRIMIDIN COMPOUNDS AND THEIR APPLICATION AS INHIBITORS MTOR KINASE AND PI3 KINASE | |
| MX340402B (en) | Tricyclic inhibitors of kinases. | |
| EA201390428A1 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF PULMONARY HYPERTENSION | |
| EA201492287A1 (en) | DEUTERED DERIVATIVES RUXOLITINIBA | |
| UA113541C2 (en) | Substituted pyrrolidine-2-carboxamides | |
| EA201300282A1 (en) | DERIVATIVES OF TRIAZOLOPIRAZINE | |
| EA201301181A1 (en) | TRIAZOLOPRYRIDINS | |
| EA201101533A1 (en) | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | |
| EA201500298A1 (en) | ALCOXYPHAZOLES AS ACTIVATORS OF SOLUBLE GUANYLATZYCLASES | |
| EA201171415A1 (en) | IAP FAMILY INHIBITORS | |
| MX337849B (en) | Compositions and methods for inhibition of the jak pathway. |